<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771731</url>
  </required_header>
  <id_info>
    <org_study_id>U54HL117664-01</org_study_id>
    <secondary_id>6610</secondary_id>
    <nct_id>NCT01771731</nct_id>
  </id_info>
  <brief_title>Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease</brief_title>
  <acronym>Cannabis-SCD</acronym>
  <official_title>Cannabinoid-Based Therapy and Approaches to Quantify Pain in Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      Our primary objective is to assess whether inhaling vaporized cannabis ameliorates chronic&#xD;
      pain in patients with sickle cell disease (SCD). As these patients will all be on chronic&#xD;
      opioid analgesics, the investigators will also assess the possible synergistic affect between&#xD;
      inhaled cannabis and opioids. The investigators will also assess the clinical safety of the&#xD;
      concomitant use of cannabinoids and these opioids in patients with SCD by monitoring the&#xD;
      short-term side effects associated with combined therapy. Finally, the investigators will&#xD;
      evaluate the short-term effects of inhaled cannabis on markers of inflammation and disease&#xD;
      progression in patients with SCD.&#xD;
&#xD;
      Hypotheses are as follows:&#xD;
&#xD;
        1. Inhaled cannabis will significantly reduce chronic pain in patients with SCD.&#xD;
&#xD;
        2. Inhaled cannabis will significantly alter the short-term side effects experienced by&#xD;
           patients who take opioids for SCD.&#xD;
&#xD;
        3. Inhaled cannabis will significantly alter markers of inflammation and disease&#xD;
           progression in patients with SCD compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a proof-of-principle investigation of the safety and potential effectiveness of&#xD;
      inhaled vaporized cannabis when added to a stable analgesic regimen in sickle cell disease&#xD;
      (SCD) patients with chronic pain. The study will be comprised of two 5-day intervention&#xD;
      periods in the inpatient setting (the Clinical Research Center at SFGH), with completion of a&#xD;
      5-day daily pain diary prior to admission to establish an outpatient baseline. Participants&#xD;
      will be randomly assigned, in double-blind fashion, to treatment with (A) vaporized cannabis&#xD;
      with an approximately 1:1 ration of delta-9-tetrahydrocannabinol:cannabidiol or (B) vaporized&#xD;
      placebo. Those who receive treatment A during the first admission will receive treatment B in&#xD;
      the second, and those who receive treatment B during the first admission will receive&#xD;
      treatment A in the second. The two admissions will be spaced at least 14 days apart.&#xD;
&#xD;
      On Day 1 of each admission, subjects will provide blood samples for baseline markers of&#xD;
      inflammation and SCD disease progression. They will undergo assessments of pain, mood, and&#xD;
      quality of life. At 12 pm on Day 1, they will inhale vaporized study agent (equivalent to 1&#xD;
      cannabis/placebo cigarette) using the VolcanoÂ® vaporizer; on Days 2-4 they will inhale study&#xD;
      agent at 8 am, 2 pm, and 8 pm, and they will inhale their final dose on Day 5 at 8 am.&#xD;
      Subjects will continue their pre-study analgesic regimen while in the study. If additional&#xD;
      analgesia is required, supplemental therapy will be administered and the dose recorded. Pain&#xD;
      measurements by visual analogue scale will be obtained every 2 hours while subjects are&#xD;
      awake. On Day 5 a second set of blood samples for inflammation markers and disease&#xD;
      progression will be obtained, and subjects will again complete pain, mood, and quality of&#xD;
      life assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">May 19, 2017</completion_date>
  <primary_completion_date type="Actual">May 12, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Rating Using Visual Analog Scale at Day 1 and Day 5</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Visual analog scale (VAS) used to assess pain. The scale range is 0-100, lower score means lower pain, higher score means higher pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <arm_group_label>Cannabis</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>marijuana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sickle cell disease, including sickle cell anemia (SS), sickle-hemoglobin C disease&#xD;
             (SC), and sickle beta thalassemia disease (Sb).&#xD;
&#xD;
          -  Ongoing opioid analgesic therapy for chronic sickle cell disease-associated pain.&#xD;
&#xD;
          -  Subjects must be on a stable dose of analgesic medication (opioid or other) for at&#xD;
             least 2 weeks before enrollment.&#xD;
&#xD;
          -  All men and women in this study must agree to use adequate birth control during this&#xD;
             study. Acceptable barrier birth control methods are a male condom, female condom,&#xD;
             diaphragm, or intra-uterine (IUD).&#xD;
&#xD;
          -  All women of reproductive potential (who have not reached menopause or undergone&#xD;
             hysterectomy, oophorectomy, or tubal ligation) must have a negative urine b-HCG&#xD;
             pregnancy test performed before initiating the protocol-specified medication.&#xD;
&#xD;
          -  Prior history of use of cannabis. Subjects must have smoked cannabis on at least 6&#xD;
             occasions in their lifetime prior to enrollment.&#xD;
&#xD;
          -  Subjects will self-report abstaining from smoking or ingesting cannabis for one week&#xD;
             prior to their enrollment into the study.&#xD;
&#xD;
          -  Able to understand and follow the instructions of the investigator, including&#xD;
             completing the pain intensity rating scales.&#xD;
&#xD;
          -  Karnofsky Performance Scale &gt;60.&#xD;
&#xD;
          -  Able and willing to provide informed consent.&#xD;
&#xD;
          -  Able and willing to spend two separate periods of 5 days and 4 nights in the Clinical&#xD;
             Research Center at SFGH.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe coronary artery disease, uncontrolled hypertension, cardiac ventricular&#xD;
             conduction abnormalities, orthostatic mean blood pressure drop greater than 24 mmHg,&#xD;
             severe chronic obstructive pulmonary disease.&#xD;
&#xD;
          -  Evidence of clinically significant hepatic or renal dysfunction based on judgment of&#xD;
             physician.&#xD;
&#xD;
          -  Positive serum THC level on Day 1 of study.&#xD;
&#xD;
          -  Active substance abuse (e.g., alcohol or injection drugs) as determined by urine&#xD;
             toxicity screening.&#xD;
&#xD;
          -  Neurologic dysfunction or psychiatric disorder severe enough to interfere with&#xD;
             assessment of pain or sensory systems.&#xD;
&#xD;
          -  Current use of smoked tobacco products.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding may not take part in this study.&#xD;
&#xD;
          -  Unable to read or speak English.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald I Abrams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Abrams DI, Couey P, Dixit N, Sagi V, Hagar W, Vichinsky E, Kelly ME, Connett JE, Gupta K. Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA Netw Open. 2020 Jul 1;3(7):e2010874. doi: 10.1001/jamanetworkopen.2020.10874.</citation>
    <PMID>32678452</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <results_first_submitted>September 3, 2019</results_first_submitted>
  <results_first_submitted_qc>August 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 7, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT01771731/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cannabis First, Then Placebo</title>
          <description>This group received active THC:CBD cannabis during their first 5-day inpatient admission and placebo during the second admission.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Cannabis</title>
          <description>This group received placebo cannabis during their first 5-day inpatient admission and THC:CBD cannabis during the second.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event: Pain Crisis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cannabis First, Then Placebo</title>
          <description>Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.&#xD;
Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Cannabis</title>
          <description>Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.&#xD;
Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" spread="12.8"/>
                    <measurement group_id="B2" value="33.3" spread="8.7"/>
                    <measurement group_id="B3" value="36.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Rating Using Visual Analog Scale at Day 1 and Day 5</title>
        <description>Visual analog scale (VAS) used to assess pain. The scale range is 0-100, lower score means lower pain, higher score means higher pain.</description>
        <time_frame>Day 1 and Day 5</time_frame>
        <population>All participants received both interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Cannabis</title>
            <description>Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Rating Using Visual Analog Scale at Day 1 and Day 5</title>
          <description>Visual analog scale (VAS) used to assess pain. The scale range is 0-100, lower score means lower pain, higher score means higher pain.</description>
          <population>All participants received both interventions.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="29.3" upper_limit="51.7"/>
                    <measurement group_id="O2" value="45.8" lower_limit="34.3" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" lower_limit="19" upper_limit="41.6"/>
                    <measurement group_id="O2" value="38.5" lower_limit="28.6" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the two 5-day admission periods separated by one month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cannabis</title>
          <description>Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Donald I. Abrams, MD</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-476-4082 ext 444</phone>
      <email>Donald.Abrams@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

